Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus ABCAMRF 85 3-Year FCF Growth Rate is 91.40% as of Jun. 2026, which is 2511% above its 10-year median of 3.50. GuruFocus rates CAMRF with a GF Score™ of 85/100 and a GF Value™ of $78.24 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,105 Biotechnology companies, Camurus AB ranks better than 98.19% on this metric.
During the past 12 months, Camurus AB's average Free Cash Flow per Share Growth Rate was 5.30% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 91.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Camurus AB was 91.40% per year. The lowest was -237.80% per year. And the median was 3.50% per year.
Camurus AB (OTCPK:CAMRF) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Camurus AB 3-Year FCF Growth Rate Related Terms
CAMRF vs VRTX, REGN, MRNA: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Camurus AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Camurus AB's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 91.40% mean?
Camurus AB (CAMRF) has a 3-Year FCF Growth Rate of 91.40% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Camurus AB and its competitors. This is 2511% above median its historical median of 3.50. According to the industry distribution chart, Camurus AB ranks #20 out of 1105 companies in the Biotechnology industry, placing it in the top 1.8%.
Is Camurus AB's 3-Year FCF Growth Rate too high?
Camurus AB's current 3-Year FCF Growth Rate of 91.40% is 2511% above median its 10-year median of 3.50. The Biotechnology industry median 3-Year FCF Growth Rate is 19.30. Camurus AB's value of 91.40% is 373.6% above this industry median. Based on the distribution chart, Camurus AB ranks #20 out of 1105 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's 3-Year FCF Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #20 out of 1105 companies for 3-Year FCF Growth Rate. This places Camurus AB in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year FCF Growth Rate is 19.30. Camurus AB's value of 91.40% is 373.6% above this benchmark. While the company's 10-year median is 3.50 vs. the industry median of 19.30, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.30, based on 1,105 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current 3-Year FCF Growth Rate of 91.40% is 373.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Camurus AB and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current 3-Year FCF Growth Rate is 91.40%, which is 2511% above median its own 10-year median of 3.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $78.24, compared to a current price of $61.75 — trading 21.1% below its estimated fair value. The current 3-Year FCF Growth Rate is 91.40%, which is 2511% above median its 10-year median of 3.50 and 373.6% above the Biotechnology industry median of 19.30. Camurus AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Camurus AB (CAMRF), the current 3-Year FCF Growth Rate is 91.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $61.75 is trading 21.1% below its estimated GF Value™ of $78.24.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
3-Year FCF Growth Rate: 91.40% (2511% above median its 10-year median of 3.50)
GF Value™: $78.24 vs. price of $61.75 (21.1% below fair value)
Industry Position: 373.6% above the Biotechnology median (#20 of 1105)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
85GF Score
Get the complete analysis for CAMRF
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
